A Study of LY4175408 in Participants With Advanced Cancer

Part of paid clinical trials in Stanford, California.

Sponsor
Eli Lilly and Company
Study ID
NCT07046923
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LY4175408 — DRUG
    IV infusion
  • Pembrolizumab — DRUG
    IV infusion
  • Carboplatin — DRUG
    IV infusion
  • Cisplatin — DRUG
    IV infusion

Study Details

The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.

Key Dates

Start date
Jul 28, 2025
Status verified
May 2026
Primary completion
Jul 31, 2030
Completion
Jul 31, 2030

Study Design

Enrollment
240 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1a Dose Escalation (Cohort A1)
    Escalating doses of LY4175408 administered intravenously (IV)
  • Experimental: Phase 1a Dose Optimization (Cohort A2)
    Two or more doses of LY4175408 (evaluated during dose escalation) administered IV
  • Experimental: Phase 1b Dose Expansion (Cohort B1)
    LY4175408 administered IV followed by pembrolizumab administered IV
  • Experimental: Phase 1b Dose Expansion (Cohort B2)
    LY4175408 administered IV followed by pembrolizumab administered IV and either carboplatin administered IV or cisplatin administered IV
  • Experimental: Phase 1b Dose Expansion (Cohorts C1, C2 and C3)
    LY4175408 administered IV

Primary Outcome Measure

Phase 1a-Number of Participants with Dose Limiting Toxicities of LY4175408 [ Time Frame: 1 Cycle (21 days) ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (15)

FacilityCityStateZIPSite coordinators
Stanford Medicine Cancer CenterStanfordCalifornia94305-
Florida Cancer Specialists - Lake Nona - Sarah Cannon Research InstituteOrlandoFlorida32827-
Florida Cancer Specialists - SarasotaSarasotaFlorida34236-
The University of Chicago Medical Center (UCMC)ChicagoIllinois60637-
Community Health NetworkIndianapolisIndiana46250-
Massachusetts General HospitalBostonMassachusetts02114-
Washington UniversitySt LouisMissouri63110-
John Theurer Cancer Center At Hackensack UMCHackensackNew Jersey07601-
Columbia UniversityNew YorkNew York10032-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
The Ohio State University (OSU) Wexner Medical CenterColumbusOhio43210-
Sarah Cannon Research InstituteNashvilleTennessee37203-
MD Anderson Cancer CenterHoustonTexas77030-
START Mountain RegionWest Valley CityUtah84119-
NEXT VirginiaFairfaxVirginia22031-

Find similar trials in Stanford, CA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Stanford Medicine Cancer Center· Stanford, CAFlorida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute· Orlando, FLFlorida Cancer Specialists - Sarasota· Sarasota, FLThe University of Chicago Medical Center (UCMC)· Chicago, ILCommunity Health Network· Indianapolis, INMassachusetts General Hospital· Boston, MA

Related Studies